Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates

Metagenomi Therapeutics reported a quarterly loss of $0.61 per share, slightly worse than the Zacks consensus estimate of a $0.60 loss, but improved from a $0.68 loss a year ago. The report is largely in line with expectations and reflects modest year-over-year progress in profitability. No revenue or guidance details were provided, limiting the likely market impact.

Analysis

Metagenomi Therapeutics reported a quarterly loss of $0.61 per share, slightly worse than the Zacks consensus estimate of a $0.60 loss, but improved from a $0.68 loss a year ago. The report is largely in line with expectations and reflects modest year-over-year progress in profitability. No revenue or guidance details were provided, limiting the likely market impact.